TRAVERE THERAPEUTICS, INC.
TVTX · Healthcare · $5.2B mkt cap · FY2025 filings · Shallow moat ·
Doesn't clear the bar
The four filters
Median gross margin 96.8% over 10y, very stable.
Median ROIC -110.1%, above the 9% hurdle in 0% of years.
Net debt/EBITDA n/ax, interest coverage -6x.
Owner earnings trend unclear, share count growing (dilution).
Margin of safety
- Owner earnings (normalized)
- —
- Est. intrinsic value / share
- —
- Recent price
- $56.71
- Discount to value
- No price data
Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).
15 years of fundamentals
The business, in plain English
TRAVERE THERAPEUTICS, INC. booked $490.7M of revenue in FY2025 in the Healthcare sector and kept 97.9% of it as gross profit — a high-margin business by that measure. After every other cost, −5.2% of each revenue dollar reached the bottom line.
It earned −227.7% on invested capital in FY2025, with a median of −89.2% across 10 filed years. The Returns on Capital filter above scores it 0/100.
TVTX's filings don't disclose total debt in a form the methodology can use, so leverage is treated as unmeasured — never assumed to be zero.
The share count rose 2149.3% between FY2011 and FY2025 — existing owners have been diluted over the record. Capital Discipline scores it 24/100.
Put together: Pricing Power is the strongest of the four filters (100/100) and Returns on Capital the weakest (0/100), which is how TVTX lands at 40/100 — a Shallow moat.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
Gaps in a line mean that item isn’t in TVTX’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Moat Score history
Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.
Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars
None yet — TVTX has read Shallow moat for every logged capture since Jul 17, 2026.
Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.
Healthcare context
#242 of 440 scored Healthcare companies, ranked by Moat Score.
Nearest peers by Moat Score
- #240OMER OMEROS CORPORATION40.3 out of 100, Shallow moatShallow moat
- #241KIDS OrthoPediatrics Corp40.3 out of 100, Shallow moatShallow moat
- #243NPCE NEUROPACE, INC.40.3 out of 100, Shallow moatShallow moat
- #244TMCI Treace Medical Concepts, Inc.40.3 out of 100, Shallow moatShallow moat
Compare TVTX with its nearest peers →All Healthcare companies on the Index →
Common questions about TVTX
- Does TRAVERE THERAPEUTICS, INC. have an economic moat?
- Based on its FY2025 SEC filings, the Moat Index scores TRAVERE THERAPEUTICS, INC. (TVTX) 40.3 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 100, returns on capital 0, balance-sheet safety 28, capital discipline 24.
- How has TVTX's Moat Score changed over time?
- The record logs 3 readings since Jul 17, 2026; the latest reads 40.3 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.